AL Amyloidosis Market Set to Cross the Next Growth Curve as Amyloid-Targeting Therapies Move Closer to Reality Across the 8MM | Thelansis

AL amyloidosis, once managed almost entirely as a hematologic disease, is now standing at a genuine inflection point. With a newly approved subcutaneous regimen reshaping frontline care and a wave of amyloid-removal therapies advancing through the clinic, 2026 is shaping up to be a defining year for how physicians, payers, and drug developers think about this rare, organ-threatening condition. To capture this shift, Thelansis has released two companion reports - the AL Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036) and the AL Amyloidosis Emerging Therapy, Unmet Needs & TPP Insights Report (2026) - offering a complete, decision-ready view of the disease across the 8 major markets (US, EU4, UK, Japan, and China).

Executive Summary
AL amyloidosis remains a rare but increasingly recognized disorder, driven by misfolded light chains that deposit in the heart, kidneys, and nervous system. Diagnosis has historically lagged symptom onset by months, but improved cardiac imaging, wider use of free light chain assays, and growing physician awareness are steadily narrowing that gap across the 8MM, including China, where rare disease reimbursement pathways and specialist hospital networks have expanded meaningfully in the past two years.
Commercially, the 7 major markets alone were valued at roughly US$3.4 billion and are on track to surpass US$13 billion within the next decade, reflecting a sustained double-digit CAGR. Add China's fast-scaling diagnostic infrastructure and genomic medicine investment, and the 8MM opportunity looks even stronger for companies positioned early.

See the full epidemiology, patient-share modeling, and 10-year market forecast: https://thelansis.com/reports/al-amyloidosis-market-outlook-forecast/

Key Emerging Players or Therapies
The pipeline has never been this active. Beyond therapies that reduce new light-chain production, developers are now chasing something the field has lacked for decades, the ability to clear amyloid that has already deposited in organs.
• Attralus (zamubafusp alfa / AT-02) - a pan-amyloid removal (PAR) candidate designed to directly bind and clear toxic amyloid from tissue; recently granted FDA Fast Track designation, building on orphan drug status earlier in 2026, following encouraging Phase 2 data shared at the ASH Annual Meeting
• AstraZeneca (anselamimab) - an investigational anti-fibril monoclonal antibody positioned as a potential first-in-class amyloid-clearing therapy
• Caelum Biosciences (CAEL-101) - continuing clinical development targeting amyloid fibril removal
• Additional programs from Sanofi, Takeda Oncology, GSK, Astellas, Sorrento Therapeutics, Zentalis Pharmaceuticals, and HaemaLogiX round out a genuinely crowded and competitive emerging landscape

Key Current Therapies or Standard of Care
Today's frontline standard remains the daratumumab-based quadruplet, dara-CyBorD (daratumumab, cyclophosphamide, bortezomib, dexamethasone) with deep hematologic response as the immediate treatment goal. A notable regulatory milestone came with the traditional FDA approval of the subcutaneous daratumumab and hyaluronidase-fihj combination, reinforcing anti-plasma-cell therapy as the commercial and clinical anchor of AL amyloidosis care across the 8MM.

Even so, every currently approved option works "upstream", reducing the supply of toxic light chain, rather than clearing amyloid that has already built up in the heart or kidneys. That distinction is exactly where the next wave of competition is forming.

Key Market Drivers/Trends
• Rising diagnosed prevalence as cardiac biomarker testing (NT-proBNP, troponin) and free light chain assays become more routine in hematology and cardiology clinics
• Growing physician and cardiologist awareness, shortening the historically long diagnostic journey
• China and broader Asia-Pacific emerging as the fastest-growing markets, supported by expanding rare disease reimbursement lists and rapid buildout of tertiary hospital and genomic diagnostic capacity
• A visible shift in R&D focus from light-chain suppression toward amyloid-clearing biologics, setting up a more differentiated, less commoditized market by the early 2030s
• Continued interest in combination approaches pairing anti-plasma-cell therapy with amyloid-depleting agents for deeper organ recovery

Key Unmet Need & KOL Expectations
Ask any amyloidosis specialist what's still missing, and the answer is consistent: patients who achieve a strong hematologic response but are left with persistent cardiac or renal dysfunction, because no approved therapy today actually removes existing amyloid deposits. KOLs continue to point to a few clear priorities:
• Amyloid-depleting agents that can reverse, not just halt, organ damage
• Earlier and more consistent diagnosis, particularly for patients presenting with non-specific cardiac symptoms
• Better staging and monitoring tools to track organ recovery over time, not just hematologic response
• Broader access to specialist amyloidosis centers outside the largest academic hubs, especially across EU4, Japan, and China

TPP Insights
The Target Product Profile analysis maps where next-generation AL amyloidosis therapies need to land to truly change practice, durable amyloid clearance, a favorable safety and tolerability profile alongside standard-of-care backbones, meaningful improvement in cardiac and renal function endpoints, and a dosing approach that fits realistically into existing hematology-oncology treatment pathways. The report benchmarks pipeline candidates against these criteria to flag which programs are positioned to set the next standard of care.
Access the full AL Amyloidosis TPP framework and emerging-therapy assessment: https://thelansis.com/reports/al-amyloidosis-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pr&utm_campaign=al_tpp

Commercial Opportunity
With an approved backbone therapy now firmly established and a genuinely differentiated wave of amyloid-clearing candidates advancing through the clinic, AL amyloidosis is moving from a niche hematology indication toward a competitive, high-value rare disease market. Companies that can demonstrate true organ-function recovery, not just hematologic response, have a real opportunity to capture premium positioning as the standard of care evolves through 2036. China's expanding diagnostic and reimbursement infrastructure adds a meaningful growth lever on top of the traditional 7MM, making the 8MM view essential for anyone building a launch or investment strategy in this space.

For a complete, data-backed view of the AL amyloidosis opportunity - epidemiology, competitive landscape, 10-year forecast, emerging therapies, unmet needs, and TPP benchmarking across the 8MM -
AL Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036): https://thelansis.com/reports/al-amyloidosis-market-outlook-forecast/?utm_source=openpr&utm_medium=pr&utm_campaign=al_mo
AL Amyloidosis Emerging Therapy, Unmet Needs & TPP Insights Report (2026): https://thelansis.com/reports/al-amyloidosis-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pr&utm_campaign=al_tpp

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.